The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
NCT06489457 on ClinicalTrials.gov · last registry update 2024-07-08
A small phase 3 — 25 participants, against a typical 424. The sponsor logged completion for 11 May 2023. Primary outcome, as filed: Change in semen volume from baseline and between the treatment arms. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 25
- Started
- 2020-09-20
- Primary completion
- 2023-05-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in semen volume from baseline and between the treatment arms
Conditions studied
Type 2 Diabetes Mellitus · Obesity · Functional Hypogonadism
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.